Science

Experimental Lung Cancer Drug Shows Early Promise

CAPR logo

By Frank Blanchard, Staff Writer

A first-of-its-kind drug is showing early promise in attacking certain lung cancers that are hard to treat because they build up resistance to conventional chemotherapy.

The drug, CO-1686, performed well in a preclinical study involving xenograft and transgenic mice, as reported in the journal Cancer Discovery. It is now being evaluated for safety and efficacy in Phase I and II clinical trials.

Tags: 

How Asking a Very Basic Research Question Led Us to a Model for at Least Three Diseases

Portrait of Howard Young

By Howard Young

Editor’s note: This article is adapted from Dr. Young’s January 12, 2015, post to the I am Intramural Blog of the Intramural Research Program.

When I started this project, it was not my objective to develop a model for any specific disease, nor did I even suspect that the ultimate result would be some insight into autoimmune disease. The basic research question I was asking was why there are sequences in the 3? untranslated region (3?UTR) of the interferon-gamma (IFN-gamma) mRNA that are more highly conserved than in the coding region of the gene.

Tags: 

NCI Scientists Awarded National Medal of Technology and Innovation by President Obama

Schiller, Lowy, President Obama, and military aide holding medal at ceremony.

Two NCI scientists received the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement. The award was announced by President Obama in October. The honorees, John Schiller, Ph.D., Laboratory of Cellular Oncology (LCO), Center for Cancer Research, NCI, and Douglas Lowy, M.D., also from LCO and NCI deputy director, received their medals at a White House ceremony on Nov. 20.

Tags: 

Pages

Subscribe to Science